*TEST COURSE* Precision Oncology in Lung Cancer: Advancing Personalized Immunotherapy and Targeted Therapies in NSCLC and SCLC

TEST COURSE Precision Oncology in Lung Cancer: Advancing Personalized Immunotherapy and Targeted Therapies in NSCLC and SCLC

Overview

This comprehensive CE activity brings together cutting-edge insights into the evolving landscape of lung cancer treatment, focusing on both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Dr. George Simon reviews immunotherapy strategies in NSCLC, focusing on optimizing first- and second-line treatment by PD-L1 levels, TMB, and KRAS/STK11 mutations. Topics include chemo-immunotherapy across PD-L1 subsets, dual checkpoint blockade in high TMB, and emerging ADCs like saxituximab govitecan. The Poseidon trial and novel RAS-targeted therapies are also discussed. Dr. Bruna Pellini reviews key advances in NSCLC targeted therapy, including FLORA-2 data favoring osimertinib over durvalumab in unresectable stage III EGFR-mutant disease and updated stage IV guidance. She also discusses molecular-based treatment with lorlatinib (ALK), ribociclib (ROS1), and trastuzumab deruxtecan (HER2), along with insights from the Mariposa and Remos trials. Dr. Triparna Sen highlights advances in SCLC therapy, including immunotherapy in all stages and survival gains with durvalumab per the Adriatic trial. Emerging treatments like T-cell engagers (e.g., terlatimab) and ADCs targeting DLL3, B7H3, and TROP2 are reviewed, with focus on biomarkers and ongoing research to personalize care. By the end of this activity, participants will be equipped with the knowledge to apply precision medicine principles and the latest clinical evidence to optimize treatment decisions across the spectrum of lung cancer care.

Objectives

Upon completion of this activity learners will be better able to:

Integrate PD-L1 expression, tumor mutational burden (TMB), and mutational profiles (e.g., KRAS/STK11) to guide personalized first- and second-line immunotherapy strategies in NSCLC.
Evaluate the role of novel therapeutic agents, including dual checkpoint inhibitors and antibody-drug conjugates, in optimizing outcomes for NSCLC patients with varying immunotherapy responses.
Apply current evidence-based guidelines to select optimal targeted therapies for patients with unresectable stage III and stage IV EGFR-mutated NSCLC.
Differentiate between recommended targeted therapies for NSCLC based on oncogenic driver mutations, including ALK, ROS1, and HER2 alterations, to personalize treatment strategies.
Evaluate emerging immunotherapy strategies and trial data to optimize treatment decisions in both extensive and limited-stage small cell lung cancer (SCLC).
Assess the clinical potential of novel targeted therapies—including T-cell engagers and antibody-drug conjugates (ADCs)—and their role in advancing personalized treatment approaches in SCLC.

Target Audience

Physicians, Nurses, Pharmacists, Physician Associates

Credit Information

Number of Credits

Credit Type(s)

AMA PRA Category 1 Credit
ANCC Credit
ACPE Credit
AAPA Category 1 CME Credit
Other
Dietitian CPEU Certificate
Social Worker CE Certificate
Dentist CE Certificate

Faculty

George R. Simon, MD, FACP, FCCP | Ohio Health

Bruna Pellini | Moffitt Cancer Center

Tripirna Sen, PhD | Icahn School of Medicine at Mount Sinai NY

Disclosure

FACULTY

George R. Simon, MD, FACP, FCCP

Consultant: RefleXion, Inc., Onc. AI, SmarTrial Inc.

Bruna Pellini, MD

Grant/Research Support: Bristol Meyers Squibb Foundation (ended), Bristol Meyers Squibb (ended).

Consultant: Foundation Medicine, Gilead, Bayer (ended), Guidepont (ended)

Advisory Board: AstraZeneca, Illumina (ended), Regeneron (ended), AH Merus (ended), Guardant Health (ended)

Speakers’ Bureau: Merck/MSD, Foundation Medicine

Other: Scientific Steering Committee - Gilead

Triparna Sen, PhD

Consultant: Jazz Pharmaceuticals

PLANNING COMMITTEE

Dina B. Dumercy McHenry, PharmD, MBA, BCOP

Has no relevant financial relationships

Luis E. Raez, MD, FACP, FASCO

Grant/Research Support: BMS, Genentech. AstraZeneca, Bayer, Lily Oncology, Loxo Pharmaceuticals, Velos, BioAlta, Guardant, Natera, ARCUS, Merck, Turning Point, ONC4, AnHeart

Consultant: AstraZeneca, Merck, Lily Oncology, Novartis, BMS

Accreditation Statement

In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician

The Medical Educator Consortium designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learner participation will be shared through the ACCME’s Program and Activity Reporting System (PARS)

Nurse

The Medical Educator Consortium designates this activity for 1.0 ANCC credit.

Pharmacist

This Application-based activity has been approved for 1.0 contact hour (0.10 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-XXX. Your CE credits will be electronically submitted to CPE Monitor^® within 60 days upon successful completion of the activity.

Physician Associate

The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.